What is the recommended management for a patient with an ejection fraction of 40% and fractional shortening of 20%?

Management of Heart Failure with EF 40% and FS 20%

This patient has heart failure with reduced ejection fraction (HFrEF) and requires immediate initiation of four foundational drug classes simultaneously: an ACE inhibitor (or ARB/ARNI), a beta-blocker (carvedilol, metoprolol succinate, or bisoprolol), a mineralocorticoid receptor antagonist (MRA), and an SGLT2 inhibitor, along with diuretics as needed for volume management.

Core Pharmacologic Strategy

The management approach has evolved from sequential drug initiation to rapid, simultaneous implementation of guideline-directed medical therapy (GDMT). With an EF of 40%, this patient sits at the threshold defining HFrEF and requires aggressive treatment to reduce mortality and prevent disease progression 1, 2, 3.

The Four Foundational Drug Classes (All Class I Recommendations)

1. Renin-Angiotensin System Inhibition

• Start with an ACE inhibitor immediately 1, 2, 3
• Consider sacubitril/valsartan (ARNI) even as initial therapy - newer guidelines support this approach without requiring prior ACE inhibitor exposure 2, 3
• If ACE inhibitor intolerant, use an ARB 1, 2
• Target doses proven effective in trials, not just blood pressure control 4, 5

2. Beta-Blockers

• Use only evidence-based agents: carvedilol, metoprolol succinate, or bisoprolol 1, 2, 3
• These specific agents have demonstrated mortality reduction 1
• Start low and uptitrate to target doses within 6-12 weeks 6

3. Mineralocorticoid Receptor Antagonists

• Spironolactone or eplerenone 1, 2, 3
• Critical monitoring requirement: Check potassium and renal function closely, especially when combining with ACE inhibitors/ARBs 1, 2
• Particularly important if patient has recent cardiovascular hospitalization, elevated natriuretic peptides, or NYHA class II-IV symptoms 2, 7

4. SGLT2 Inhibitors

• Empagliflozin or dapagliflozin 3, 6, 8
• Start regardless of diabetes status 8
• These reduce mortality and HF hospitalizations 3
• Advantage: minimal blood pressure lowering effect, making them ideal for patients with borderline low BP 9

Practical Implementation Algorithm

Step 1: Initial Assessment

• Confirm volume status (adjust diuretics accordingly)
• Check baseline potassium, creatinine, blood pressure, heart rate
• Assess for contraindications to each drug class

Step 2: Simultaneous Initiation Strategy

Start all four drug classes together at low doses 8, 10:

• SGLT2 inhibitor and MRA can be started first as they don't significantly lower BP 9
• Then add low-dose ACE inhibitor (or ARNI at 24/26 mg twice daily)
• Add beta-blocker if heart rate >70 bpm 9

Step 3: Rapid Uptitration

• Uptitrate one drug at a time using small increments 9
• Target maximum tolerated or guideline-recommended doses within 6-12 weeks 6
• Monitor weekly during uptitration phase 9

Managing Common Challenges

If Blood Pressure is Borderline Low

The fractional shortening of 20% (normal >25%) suggests significant systolic dysfunction, but if BP is marginal 9:

• Prioritize SGLT2i and MRA first - minimal BP effect
• Use very low-dose sacubitril/valsartan (25 mg twice daily) or low-dose ACE inhibitor
• Consider selective β₁-blockers (metoprolol, bisoprolol) over non-selective agents with vasodilatory properties
• If beta-blocker not tolerated, ivabradine is an alternative if patient is in sinus rhythm with HR >70 bpm 9

Monitoring for Adverse Effects

Hyperkalemia Risk (most critical with MRA + ACE inhibitor/ARB combination):

• Check potassium within 1 week of initiation and after each dose increase 2
• Potassium must be <5.2 mmol/L before adding MRA 2
• If hyperkalemia develops, adjust doses rather than discontinue entirely

Renal Function:

• Some creatinine elevation (up to 30% increase) is acceptable and doesn't require drug discontinuation 2
• Monitor eGFR - must be ≥30 mL/min/1.73 m² for ARNI 2

Hypotension:

• Asymptomatic low BP doesn't require dose reduction 9
• Symptomatic hypotension: reduce or eliminate non-HF antihypertensives first 9
• Adjust diuretics if overdiuresis suspected

Additional Therapies

Diuretics:

• Loop diuretics for volume control (Grade D) 1, 2
• Thiazide/thiazide-like diuretics for BP control if needed (Grade B) 2
• Adjust based on volume status, not fixed dosing

If ACE Inhibitors and ARBs Contraindicated:

• Hydralazine plus isosorbide dinitrate combination (Grade B) 1, 2

Secondary Therapies (for persistent symptoms despite GDMT):

• Ivabradine if sinus rhythm with HR >70 bpm despite beta-blockers 9
• Digoxin for rate control in atrial fibrillation
• Vericiguat after recent decompensation 8

Critical Pitfalls to Avoid

1. Don't delay treatment waiting to uptitrate one drug before starting another - simultaneous initiation is now standard 8, 10

2. Don't use non-evidence-based beta-blockers - only carvedilol, metoprolol succinate, and bisoprolol have proven mortality benefit 1

3. Don't stop medications for asymptomatic hypotension - low BP without symptoms is common and acceptable in HFrEF 9

4. Don't combine ACE inhibitor + ARB in coronary disease without HF - but this combination may be used in HFrEF with careful monitoring 5

5. Don't undertitrate - target the doses proven effective in clinical trials, not just symptom relief 4, 5

Trajectory Monitoring

With EF at exactly 40%, this patient is at the HFrEF threshold. Repeat echocardiography in 3-6 months to assess:

• Response to therapy (many patients improve EF with GDMT)
• If EF improves to 41-49% (HFmrEF), continue all therapies 3, 11
• If EF remains ≤40%, consider device therapy evaluation (ICD, CRT) if QRS prolonged 3

The evidence strongly supports that patients at the lower end of the EF spectrum (40-45%) respond similarly to those with more severely reduced EF and should receive identical aggressive GDMT 3, 11.